Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 12, 2024, discloses the granting of Deferred Annual Bonus Plan (DABP) awards to Persons Discharging Managerial Responsibilities (PDMRs) on February 8, 2024. The awards are issued under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan, requiring executives to defer portions of their bonuses into Ordinary Shares or American Depositary Shares (ADS) for a three-year period.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation transactions. The specific transaction details are as follows:
- Transaction Date: February 8, 2024
- Instrument Type: Ordinary Shares (GBP) and American Depositary Shares (USD)
- Share Price (Ordinary Shares): £16.726
- Share Price (ADS): $42.02
- Total Volume (Ordinary Shares): 580,029 shares
- Total Volume (ADS): 17,987 shares
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It serves as a regulatory notification of a routine executive compensation event.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not disclose new risks or contingencies. The only noted condition is the three-year deferral period for the awarded shares, during which dividend reinvestment will accrue.
Important Facts for Investors
- Executive Participation: Awards were granted to 12 senior executives, including CEO Emma Walmsley (147,271 shares) and CFO Julie Brown (56,190 shares).
- Deferral Requirements: Executive Directors must defer 50% of bonuses up to 200% of salary, with the remainder deferred in full. Other leadership team members must defer 25% of bonuses up to 170% of salary.
- Instrument Allocation: Most participants received Ordinary Shares; only one participant (Chief Digital and Technology Officer Shobie Ramakrishnan) received ADS.
- Valuation Basis: The share counts listed are exclusive of dividend reinvestment that will accrue during the deferral period.